文献速递浆细胞疾病

B细胞成熟抗原导向嵌合抗原受体T细胞治疗后复发多发性骨髓瘤的挽救治疗包括再次B细胞成熟抗原导向治疗

Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性分析纳入68例B细胞成熟抗原导向嵌合抗原受体T细胞治疗后复发的多发性骨髓瘤患者,中位随访13.5个月,复发后中位总生存18个月(95%CI 13.2至未达到)。58例接受后续治疗共265线,首次挽救治疗总缓解率41%(95%CI 28-55),再次B细胞成熟抗原导向嵌合抗原受体T细胞、双特异性抗体等显示较高缓解率但缓解持续时间有限。

要点

  • 复发后中位总生存18个月(95%CI 13.2至未达到),中位随访13.5个月。
  • 首次挽救治疗总缓解率41%(95%CI 28-55),58例接受后续治疗共265线。
  • 再次B细胞成熟抗原导向嵌合抗原受体T细胞、双特异性抗体等缓解率高但缓解持续时间有限。

核心结论

  • 再次B细胞成熟抗原导向嵌合抗原受体T细胞和双特异性抗体可作为B细胞成熟抗原导向嵌合抗原受体T细胞治疗后复发的有效挽救选择,但缓解持续时间似乎有限,需要新联合方案和替代靶点的进一步研究。

研究设计与样本

  • 回顾性分析68例B细胞成熟抗原导向嵌合抗原受体T细胞治疗后复发的多发性骨髓瘤患者,评估挽救治疗结局和缓解。

主要发现

  • 中位随访13.5个月,复发至死亡的中位总生存为18个月(95%CI 13.2至未达到)。
  • 58例接受后续骨髓瘤导向治疗,共265线治疗;首次挽救治疗总缓解率41%(95%CI 28-55)。
  • 所有治疗线中,再次B细胞成熟抗原导向嵌合抗原受体T细胞缓解率89%,B细胞成熟抗原导向双特异性抗体60%,CD38导向联合方案与双特异性抗体联合时80%、与免疫调节药物和/或蛋白酶体抑制剂联合时50%,烷化剂联合方案总体50%、大剂量烷化剂时69%。
  • 34例接受至少1线挽救性B细胞成熟抗原导向治疗,后续B细胞成熟抗原导向嵌合抗原受体T细胞、双特异性抗体和belantamab mafodotin的中位无进展生存分别为8.3个月(95%CI 7.9至未达到)、3.6个月(95%CI 1.4至未达到)和1个月(95%CI 0.9至未达到),中位缓解持续时间分别为8个月、4.4个月和2.8个月。

局限性

  • 原文为回顾性分析。
  • 缓解持续时间似乎有限。
  • 需要新联合方案和替代靶点的进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with relapsed/refractory multiple myeloma with a relapse after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T), optimal salvage treatment strategies remain unclear. BCMA-directed CAR-T and bispecific antibodies (BsAbs) are now commercially available, and the outcomes for retreatment with BCMA-directed approaches are not well studied. We performed a retrospective analysis of 68 patients with relapsed disease after BCMA-directed CAR-T to evaluate outcomes and responses to salvage therapies. With a median follow-up of 13.5 months, median overall survival from time of relapse until death was 18 months (95% confidence interval [CI], 13.2 to not reached [NR]). Fifty-eight patients received subsequent myeloma-directed therapies, with a total of 265 lines of therapy (LOTs). The overall response rate for firstline salvage therapy was 41% (95% CI, 28-55). Among all LOTs, high response rates were observed among those receiving another BCMA-directed CAR-T (89%), BCMA-directed BsAbs (60%), CD38-directed combinations (80% when combined with BsAb; 50% when combined with immunomodulatory drugs and/or proteasome inhibitors), and alkylator-combinations (50% overall; 69% with high-dose alkylators). Thirty-four patients received at least 1 line of salvage BCMA-directed therapy; median progression-free survival was 8.3 months (95% CI, 7.9 to NR), 3.6 months (95% CI, 1.4 to NR), and 1 month (95% CI, 0.9 to NR) with median duration of response (DOR) of 8 months, 4.4 months, and 2.8 months for subsequent BCMA-directed CAR-T, BsAb, and belantamab mafadotin, respectively. Retreatment with BCMA-directed CAR-T and BsAbs can be effective salvage options after BCMA-directed CAR-T relapse; however, DORs appear limited, and further studies with new combinations and alternative targets are warranted.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Reyes KR, Liu YC, Huang CY, et al. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Blood Adv. 2024. PMID: 38429087. doi:10.1182/bloodadvances.2023012066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。